CADL - Company ID 0001841387
The table below shows Candel Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $125.00K | $125.00K | $125.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $30.50M | $19.31M | $24.51M | $20.79M | $15.18M | $8.75M |
| SG&A |
Candel Therapeutics, Inc. reported annual revenue of $125.00K for fiscal year 2022. That is up 0.0% from $125.00K in fiscal 2021. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $17.77M |
| $14.06M |
| $13.88M |
| $14.06M |
| $10.67M |
| $5.18M |
| Operating income | -$48.27M | -$33.37M | -$38.39M | -$34.72M | -$25.73M | -$13.81M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | - |
| Net income | -$38.18M | -$55.18M | -$37.94M | -$18.79M | -$36.12M | -$17.68M |
| EPS (diluted) | -$0.72 | -$1.74 | -$1.31 | -$0.65 | -$1.91 | - |